Abstracts tagged "Cutaneous"

Abstract Number: 1848 • ACR Convergence 2022
Characterizing Nailfold Capillary Changes in Dermatomyositis with a Dermatoscope
Josh Dan¹, Grant Sprow², Josef Concha³, Nilesh Kodali⁴, DeAnna Diaz⁵, Felix Chin⁶, Thomas Vazquez⁷ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ²Albert Einstein College of Medicine, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴New Jersey Medical School, Coppell, TX, ⁵Philadelphia College of Medicine, Philadelphia, PA, ⁶University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁷FIU Wertheim College of Medicine, Virginia Beach, VA
Background/Purpose: Nailfold capillary (NC) abnormalities are increasingly utilized in the evaluation of rheumatic conditions. Their presence can distinguish primary Raynaud's phenomenon from secondary etiologies and…
Abstract Number: 0318 • ACR Convergence 2022
Development and Validation of Algorithms to Identify Cutaneous Lupus Patients Using Diagnostic Codes and Prescription Data
Lisa Guo¹, Jordan Said², Vinod Nambudiri³ and Joseph Merola³, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Harvard Medical School, Brigham and Women's Hospital, Boston, MA
Background/Purpose: There is a paucity of epidemiological studies of cutaneous lupus erythematosus (CLE), which may be due in part to the lack of well-validated methods…
Abstract Number: 1862 • ACR Convergence 2022
Lenabasum Reduces IFNγ and pIRF3 in Dermatomyositis Skin: Biomarker Results from a Double-Blind Phase 3 International Randomized Controlled Trial
Thomas Vazquez¹, Meena Sharma¹, Rui Feng², DeAnna Diaz³, Nilesh Kodali¹, Josh Dan³, Madison Grinnell³, Emily Keyes³, Grant Sprow³, Barbara White⁴ and Victoria Werth³, ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Corbus Pharmaceuticals, Pleasanton, CA
Background/Purpose: Dermatomyositis (DM) is an autoimmune connective tissue disease that primarily affects the skin and lung; few effective treatment options are available. Lenabasum is a…
Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Mariko Ogawa-Momohara¹, Thomas Vazquez², Meena Sharma², Josh Dan³, Grant Sprow³ and Victoria Werth³, ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…
Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Thomas Vazquez¹, Nilesh Kodali¹, DeAnna Diaz², Jay Patel³, Emily Keyes², Grant Sprow², Meena Sharma¹, Mariko Ogawa-Momohara², Madison Grinnell², Josh Dan² and Victoria Werth², ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
Abstract Number: 0348 • ACR Convergence 2022
Significant Improvement in Cutaneous Lupus Erythematosus with or Without Systemic Lupus Erythematosus with Belimumab Use – a Systematic Review and Meta-Analysis
Rachel Kneeland¹, Daniel Montes¹, Justin endo¹, Bridget Shields¹, Christie Bartels² and Shivani Garg³, ¹University of Wisconsin, School of Medicine and Public Health, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Madison, School of Medicine and Public Health, Madison, WI
Background/Purpose: Cutaneous lupus erythematosus (CLE) with or without systemic lupus erythematosus (SLE), can be debilitating and cause significant scarring and psychological distress. Belimumab, a monoclonal…
Abstract Number: 0364 • ACR Convergence 2022
Efficacy of BIIB059 on Joint and Skin Manifestations in Participants with Systemic Lupus Erythematosus (SLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part A)
Richard Furie¹, Ronald van Vollenhoven², Victoria Werth³, Kenneth Kalunian⁴, Sandra Navarra⁵, Juanita Romero-Diaz⁶, Ting Wang⁷, Cristina Musselli⁷, Catherine Barbey⁸ and Nathalie Franchimont⁷, ¹Northwell Health, Great Neck, NY, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of California San Diego, La Jolla, CA, ⁵University of Santo Tomas, Manila, Philippines, ⁶Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁷Biogen, Cambridge, MA, ⁸Biogen, Baar, Switzerland
Background/Purpose: SLE is a heterogeneous illness that often manifests with skin and/or joint diseases.1 BIIB059 is a humanized monoclonal antibody that binds to BDCA2, a…
Abstract Number: 0365 • ACR Convergence 2022
Improvements in Skin Manifestations with BIIB059 Measured by CLASI in Participants with Cutaneous Lupus Erythematosus (CLE): Exploratory Analyses of the Phase 2, Randomized, Double-Blind, Placebo-Controlled LILAC Study (Part B)
Victoria Werth¹, Ronald van Vollenhoven², Richard Furie³, Filippa Nyberg⁴, Kenneth Kalunian⁵, Sandra Navarra⁶, Juanita Romero-Diaz⁷, Wenbin Zhu⁸, Catherine Barbey⁹, Cristina Musselli⁸ and Nathalie Franchimont⁸, ¹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Northwell Health, Great Neck, NY, ⁴Karolinska University Hospital, Stockholm, Sweden, ⁵University of California San Diego, La Jolla, CA, ⁶University of Santo Tomas, Manila, Philippines, ⁷Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, ⁸Biogen, Cambridge, MA, ⁹Biogen, Baar, Switzerland
Background/Purpose: BIIB059 is a humanized monoclonal antibody against BDCA2, a receptor exclusively expressed on plasmacytoid dendritic cells, which are implicated in the pathogenesis of cutaneous…
Abstract Number: 0556 • ACR Convergence 2022
Immune Checkpoint VISTA Regulates Type I Interferon (IFN-I) Production and Controls UV Light Triggered Skin IFN-I Response
Zachary Peters¹, Lindsay Mendyka¹, Sicong Shan¹, Angelique Cortez¹, William Rigby², Christopher Burns¹, Randolph Noelle³ and Sladjana Skopelja-Gardner¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth Hitchcock Medical Center, Lebanon, PA, ³Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: Most lupus patients chronically exhibit higher IFN-I scores in the skin, peripheral blood, and kidneys that is exacerbated by ultraviolet (UV) light. In normal…
Abstract Number: 0661 • ACR Convergence 2022
Cutaneous Type I IFN Responses in Systemic Lupus Erythematosus Are Associated with Inflammatory Phenotype and Altered Wound Healing Function of Lupus Fibroblasts from Non-Lesional Skin
Lisa Abernathy-Close, Suzanne Shoffner-Beck, Annie Lu, Amanda Victory, Amy Hurst, Craig Dobry, Rachael Wasikowski, Johann Gudjonsson, Alex Tsoi and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogenous, disfiguring, and difficult-to-treat manifestation of systemic lupus erythematosus (SLE) with scar formation in CLE subtypes such as…
Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Lucy Marie Carter¹, Zoe Wigston¹, Jack Arnold¹ and Philip Laws², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
Abstract Number: 0970 • ACR Convergence 2021
Hippo Signaling Is a Novel Regulator of Apoptosis and Photosensitivity in Lupus Keratinocytes
Grace Hile¹, Patrick Coit², Bin Xu¹, Shannon Estadt¹, Jacob Martens³, Rachael Wasikowski¹, Lam Tsoi¹, Ramiro Iglesias-Bartolome⁴, Celine Berthier¹, Allison Billi⁵, Johann Gudjonsson⁵, Amr Sawalha² and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Pittsburgh, Pittsburgh, PA, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁴NIH, National Cancer Institute, Bethesda, MD, ⁵Department of Dermatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Skin inflammation and photosensitivity are common manifestations of cutaneous (CLE) and systemic lupus erythematosus (SLE), yet the mechanisms underlying heightened cell death and epidermal…
Abstract Number: 1043 • ACR Convergence 2021
Prevalence of Multimorbidity in Cutaneous Lupus Erythematosus: A Population-Based Study
Mehmet Hocaoglu¹, Mark Davis², Maria Valenzuela-Almada³, Jesse Dabit², Shirley-Ann Osei-Onomah², Sebastian Vallejo-Ramos², Tina Gunderson², Kurt Greenlund⁴, Kamil Barbour⁴, Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Mayo Clinic, Rochester, MN, ⁴Centers for Disease Control, Atlanta, GA, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) patients report impaired quality of life due to cutaneous and psychological morbidity. Previous literature on the prevalence of comorbidities in…
Abstract Number: 1282 • ACR Convergence 2021
Classification of Disease Activity and Damage in Cutaneous Lupus
Laila Abbas, Karabi Nandy and Benjamin Chong, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The Cutaneous Lupus Disease Area and Severity Index (CLASI) can quantify disease activity and damage in Cutaneous Lupus Erythematosus (CLE). Classification of CLASI scores…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].